$-0.19 EPS Expected for Biocept, Inc. (BIOC); VERSUS SYSTEMS (VRSSF) Shorts Up By 10%

February 19, 2018 - By Darrin Black

VERSUS SYSTEMS INCORPORATED (OTCMKTS:VRSSF) had an increase of 10% in short interest. VRSSF’s SI was 5,500 shares in February as released by FINRA. Its up 10% from 5,000 shares previously. With 74,700 avg volume, 0 days are for VERSUS SYSTEMS INCORPORATED (OTCMKTS:VRSSF)’s short sellers to cover VRSSF’s short positions. The stock decreased 3.30% or $0.009 during the last trading session, reaching $0.272. About 38,120 shares traded or 60.70% up from the average. Versus Systems Inc. (OTCMKTS:VRSSF) has 0.00% since February 19, 2017 and is . It has underperformed by 16.70% the S&P500.

Analysts expect Biocept, Inc. (NASDAQ:BIOC) to report $-0.19 EPS on March, 6.They anticipate $0.08 EPS change or 29.63% from last quarter’s $-0.27 EPS. After having $-0.20 EPS previously, Biocept, Inc.’s analysts see -5.00% EPS growth. The stock decreased 2.91% or $0.009 during the last trading session, reaching $0.3005. About 703,698 shares traded. Biocept, Inc. (NASDAQ:BIOC) has declined 31.06% since February 19, 2017 and is downtrending. It has underperformed by 47.76% the S&P500.

Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample. The company has market cap of $19.11 million. The company's cancer assays provide information to oncologists and other physicians that enable them to select personalized treatment for their patients who have been diagnosed with cancer based on molecular drivers. It currently has negative earnings. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, and melanoma.

Among 3 analysts covering Biocept Inc (NASDAQ:BIOC), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Biocept Inc had 4 analyst reports since August 19, 2015 according to SRatingsIntel. H.C. Wainwright initiated Biocept, Inc. (NASDAQ:BIOC) on Wednesday, August 19 with “Buy” rating. The firm has “Buy” rating given on Monday, June 6 by Roth Capital.

Versus Systems Inc. operates a business-to-business software platform that allows video game publishers and developers to offer prize matches of their games to their players. The company has market cap of $19.14 million. The Company’s Versus platform facilitates various types of multiplayer matches for prizes that include real-money, consumer packaged goods, and downloadable content. It currently has negative earnings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: